Your session is about to expire
← Back to Search
Survey Timing for Cardiovascular Disease Study (eFHS-2 Trial)
N/A
Waitlist Available
Led By Joanne Murabito
Research Sponsored by Boston University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 24, to completion of study usually 26 weeks
Awards & highlights
eFHS-2 Trial Summary
This trial will test if administering half of survey modules every 2 weeks will increase participants' response rates.
Who is the study for?
This trial is for English-speaking U.S. residents who can read, own a compatible iPhone or Android device, and are part of the FHS Offspring and Omni Group 1 Cohorts with an in-person exam at the FHS Research Center. They must consent to data sharing and notifications.Check my eligibility
What is being tested?
The study tests if changing how often survey modules are given affects participant response rates in a heart study app. One group gets surveys every two weeks; another gets them every four weeks over various periods totaling up to 24 weeks.See study design
What are the potential side effects?
Since this trial involves completing surveys on cardiovascular health via an app, there aren't any direct physical side effects like those associated with medications or medical procedures.
eFHS-2 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 24, to completion of study usually 26 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 24, to completion of study usually 26 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Proportion of surveys/tasks returned in period 1
Proportion of surveys/tasks returned in period 2
Proportion of surveys/tasks returned in period 3
+1 moreSecondary outcome measures
Proportion of questions/task completed per participant in period 1
Proportion of questions/task completed per participant in period 2
Proportion of questions/task completed per participant in period 3
+1 moreeFHS-2 Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental GroupExperimental Treatment1 Intervention
The experimental group will receive the physical function survey at weeks 2, 10, 18, and 26; the physical activity survey at weeks 2, 14, and 26; the events survey at weeks 2, 6, 10, 14, 18, 22, and 26. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
Group II: Control GroupActive Control1 Intervention
The control group will receive the physical function survey at weeks 0, 8, 16, and 24; the physical activity survey at weeks 0, 12, and 24; the events survey at weeks 0, 4, 8, 12, 16, 20, and 24. The administration of the cognition, pain, mood, and psychosocial surveys follow the same pattern for both groups.
Find a Location
Who is running the clinical trial?
Boston UniversityLead Sponsor
458 Previous Clinical Trials
9,945,851 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,847 Previous Clinical Trials
47,817,744 Total Patients Enrolled
Joanne MurabitoPrincipal InvestigatorFramingham Heart Study
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You can read and understand English well enough to participate in the study.You have an iPhone with iOS version 10.0 or higher or an Android with version 5.0 or higher.You have difficulty reading or are unable to read.
Research Study Groups:
This trial has the following groups:- Group 1: Experimental Group
- Group 2: Control Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger